Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA Mutations

JAMA Oncology

Volumn 2, Issue 11, 2016, Pages 1434-1440

  Shu, Catherine A ^a   Pike, Malcolm C ^b   Jotwani, Anjali R ^b   Friebel, Tara M ^c   Soslow, Robert A ^b   Levine, Douglas A ^b   Nathanson, Katherine L ^d   Konner, Jason A ^b   Arnold, Angela G ^b   Bogomolniy, Faina ^b   Dao, Fanny ^b   Olvera, Narciso ^b   Bancroft, Elizabeth K ^e   Goldfrank, Deborah J ^b   Stadler, Zsofia K ^b   Robson, Mark E ^b   Brown, Carol L ^b   Leitao, Mario M ^b   Abu Rustum, Nadeem R ^b   Aghajanian, Carol A ^b   Blum, Joanne L ^f   Neuhausen, Susan L ^g   Garber, Judy E ^c   Daly, Mary B ^h   Isaacs, Claudine ⁱ   Eeles, Rosalind A ^e   Ganz, Patricia A ^j,k,l   Barakat, Richard R ^b   Offit, Kenneth ^b   Domchek, Susan M ^d   Rebbeck, Timothy R ^c   Kauff, Noah D ^m   more..

^a Department of Medicine   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f TEXAS ONCOLOGY   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CLINICAL TRIAL; FEMALE; FOLLOW UP; GENETICS; HETEROZYGOSITY LOSS; HUMAN; HYSTERECTOMY; MIDDLE AGED; MULTICENTER STUDY; MUTATION; OVARIECTOMY; PROSPECTIVE STUDY; RISK; SALPINGECTOMY; TUMOR SUPPRESSOR GENE; UTERINE NEOPLASMS;

ADULT; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; HUMANS; HYSTERECTOMY; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MUTATION; OVARIECTOMY; PROSPECTIVE STUDIES; RISK; SALPINGECTOMY; UTERINE NEOPLASMS;

EID: 85013127981     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.1820     Document Type: Article

References (45)

1. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-1615.
2. Rebbeck TR, Lynch HT, Neuhausen SL, et al; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616-1622.
3. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-And BRCA2-Associated breast and gynecologic cancer. J Clin Oncol. 2008;26(8): 1331-1337.
4. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
5. Finch AP, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547-1553.
6. American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins-Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103. Obstet Gynecol. 2009;113(4):957-966.
7. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25 (20):2921-2927.
8. Thompson D, Easton DF; Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358-1365.
9. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91(15):1310-1316.
10. Segev Y, Iqbal J, Lubinski J, et al; Hereditary Breast Cancer Study Group. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2013;130(1): 127-131.
11. Bruchim I, Amichay K, Kidron D, et al. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer. 2010;20(7): 1148-1153.
12. Lavie O, Ben-Arie A, Segev Y, et al. BRCA germline mutations in women with uterine serous carcinoma. Int J Gynecol Cancer. 2010;20(9): 1531-1534.
13. Goshen R, ChuW, Elit L, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol. 2000;79(3):477-481.
14. Levine DA, Lin O, Barakat RR, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol. 2001;80(3):395-398.
15. Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011;54(2):278-291.
16. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Lancet Oncol. 2006;7(3):223-229.
17. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER Stat Databases: November 2012 Submission. Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (2000-2010). Katrina/Rita Population Adjustment http://seer.cancer.gov/data/seerstat/nov2012/. Released April 2013. Accessed August 27, 2015.
18. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2010.
19. Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma. Gynecol Oncol. 2015;137(3):581-588.
20. Kandoth C, Schultz N, Cherniack AD, et al; Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. [published correction in Nature. 2013 Aug 8;500(7461):242]. Nature. 2013;497(7447): 67-73.
21. Garg K, Levine DA, Olvera N, et al. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol. 2013;37(1):138-146.
22. Brozek I, Ochman K, Debniak J, et al. Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers. J Appl Genet. 2009;50 (4):379-384.
23. Pennington KP, Walsh T, LeeM, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer. 2013;119(2):332-338.
24. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer. Am J Hum Genet. 1997; 60(3):496-504.
25. ReitsmaW, Mourits MJ, de Bock GH, Hollema H. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers. Mod Pathol. 2013;26(4):572-578.
26. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
27. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26(32): 5284-5293.
28. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer. Am J Surg Pathol. 2010;34(3):433-443.
29. Jarboe EA, Miron A, Carlson JW, et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube. Int J Gynecol Pathol. 2009;28(4):308-315.
30. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2003;91(3):463-469.
31. Chan JK, Manuel MR, Cheung MK, et al. Breast cancer followed by corpus cancer. Gynecol Oncol. 2006;102(3):508-512.
32. Liang SX, Pearl M, Liang S, et al. Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Int J Cancer. 2011;128(4): 763-770.
33. Barakat RR, Wong G, Curtin JP, Vlamis V, HoskinsWJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994;55(2): 164-168.
34. Bland AE, Calingaert B, Secord AA, et al. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol. 2009;112(1):150-154.
35. Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancerl. Gynecol Oncol. 2013;129(2):277-284.
36. Wen J, Li R, Lu Y, Shupnik MA. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptorcoregulator interactions. Oncogene. 2009;28(4): 575-586.
37. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma. Curr Opin Obstet Gynecol. 2010;22(1):21-29.
38. Wright JD, Ananth CV, Lewin SN, et al. Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA. 2013;309(7):689-698.
39. Wright JD, Kostolias A, Ananth CV, et al. Comparative effectiveness of robotically assisted compared with laparoscopic adnexal surgery for benign gynecologic disease. Obstet Gynecol. 2014; 124(5):886-896.
40. Altman D, Granath F, Cnattingius S, Falconer C. Hysterectomy and risk of stress-urinaryincontinence surgery. Lancet. 2007;370(9597): 1494-1499.
41. Dällenbach P, Kaelin-Gambirasio I, Dubuisson JB, Boulvain M. Risk factors for pelvic organ prolapse repair after hysterectomy. Obstet Gynecol. 2007;110(3):625-632.
42. Lonnée-Hoffmann R, Pinas I. Effects of hysterectomy on sexual function. Curr Sex Health Rep. 2014;6(4):244-251.
43. Mäkinen J, Johansson J, Tomás C, et al. Morbidity of 10 110 hysterectomies by type of approach. Hum Reprod. 2001;16(7):1473-1478.
44. McPherson K, MetcalfeMA, Herbert A, et al. Severe complications of hysterectomy. BJOG. 2004;111(7):688-694.
45. Spilsbury K, Hammond I, BulsaraM, Semmens JB. Morbidity outcomes of 78 577 hysterectomies for benign reasons over 23 years. BJOG. 2008;115(12):1473-1483.